Oryzon Genomics S.a.

Minoryx Therapeutics S.l.

Marc Martinell Pedemonte

Matthew Colin Thor Fyfe

Alberto Ortega Muñoz

Nuria Valls Vidal

Julio Cesar Castro Palomino Laria

Guido Kurz

Maria De Los Àngeles Estiarte Martinez

Maria Pilar Pizcueta Lalanza

Julio Cesar Castro-Palomino Laria

Iñigo Tirapu Fernandez De La Cuesta

Matthew Colin Fyfe

Ana Maria García Collazo

Maria De Los Ángeles Estiarte-Martinez

David John Augustus Eckland

Maria De Estiarte-Martinez

Tamara Maes

Julio Castro Palomino

Jonathan Alleman Baker

Xavier Barril Alonso

Elena Cubero Jordà

Laura Pilar Rodríguez Pascau

Núrla Valls Vidal

María De Los Ángeles Estiarte Martínez

Ana María García Collazo

Maria De Los Ángeles Estiarte Martinez

Maria De Los Ángeles Estiarte-Martínez

Maria De Los ÁNgeles Estiarte-MARTÍNEZ

Alberto Ortega MUÑOZ

Ana María GARCÍA Collazo

Julio Castro-Palomino Laria

Elena Cubero JordÀ

Ana Maria GARCÍA Collazo

María De Los ÁNgeles Estiarte MARTÍNEZ

Laura Pilar RODRÍGUEZ Pascau

Maria De Estiarte Martinez

Inigo Tirapu Fernandez De La Cuesta

The present disclosure relates to a method of treating or preventing mitochondrial diseases by administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.

5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

The present disclosure relates to a method of treating or preventing nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid carcinoma, a thyroid autoimmune disorder, a pituitary adenoma, atherosclerosis, hypertension, a skin disease, an inflammation and autoimmune disease, and an inflammatory respiratory disease by administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.

5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease

The application is directed to compounds of formula (I):(I), and formula (IA):(IA) and their salts and solvates, wherein R, R, R, R, R, n, A, A, A, and Y are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of &#x3b2;-galactosidase, specially galactosidase beta-1 or GLB 1, including GM 1 gangliosidoses and Morquio syndrome, type B. 

Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. 

(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. 

The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.

2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.

Lysine demethylase inhibitors for myeloproliferative disorders

The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy) benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection. 

Cyclopropylamine derivatives useful as LSD1 inhibitors

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. 

Growing community of inventors

Barcelona, Spain

Marc Martinell Pedemonte